A small study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism found that men with hypersexual disorder may have higher amounts of oxytocin in their blood than men without the illness.

One of the most common symptoms of hypersexuality is a compulsion to engage in sexual acts that are out of proportion to one’s emotional state.

In the hypothalamus, the pituitary gland produces oxytocin, which is released. This hormone is crucial to sexual behavior, and it may play a role in hypersexual conditions if it is present in excessive amounts.

Blood samples from 64 men with hypersexual disorder and 38 healthy men were compared, and the researchers discovered that the oxytocin levels in the hypersexual men’s samples were greater. Cognitive-behavioral therapy helped 30 males with hypersexual dysfunction reduce their oxytocin levels following treatment.

“Oxytocin may be a possible medication target for future pharmacological treatment for sex addiction,” Chatzittofis added.

Heart and renal failure patients may benefit from gastrointestinal hormone therapy.

According to a recent study, excessive secretion in the pancreas is linked to an increase in heart and kidney function. Secretin could be an “interesting therapeutic candidate for future trials in heart and kidney failure,” according to researchers. American Journal of Physiology-Endocrinology and Metabolism released the findings ahead of print.

Deficiency in blood supply to the body causes heart failure. Patients who have kidney failure or end-stage renal disease are on dialysis or waiting for a transplant because their kidney function has declined. According to the Centers for Disease Control and Prevention (CDC), nearly 880,000 people in the United States are now being treated for kidney failure and heart failure, according to the Centers for Disease Control and Prevention (CDC). According to the experts, “renal dysfunction worsens cardiac failure and vice versa.”

In addition to its involvement in promoting pancreatic secretion, secretin is best known for its part in the digestion of nutrients. However, there has been a growing interest in its possible heart-related effects. Secretin receptors can be found in many different body parts, including the kidneys and the hearts.

In a blind crossover trial, 15 healthy men were evaluated by Turku University researchers. Particle emission tomography and computed tomography were used to scan each subject twice while fasting. As a comparison, one scan was performed while secretin was administered intravenously, while the other was performed while saline was administered intravenously.

A radioisotope tagged glucose was also administered to the subjects, allowing researchers to track the glucose’s movement through the body. They also measured estimated glomerular filtration rates (eGFR), a common indicator of kidney function, at several stages during the therapies.

Greater glucose absorption was discovered in the heart muscle during the secretin treatment compared to the control, evidence of improved heart function. During the secretin intervention, the kidneys of the individuals filtered out more of the labeled glucose than during the saline treatment. eGFR climbed at the same time that secretin peaked, further indicating improved kidney function.

Secretin may be useful in treating heart failure in the future, the researchers say. “Based on the present findings, we believe that further trials are necessary.”

Leave a Comment